Roche-backed Dicer­na push­es in­to the pack rac­ing to­ward the block­buster hep B goal line, armed with PhI da­ta

Dicer­na has lined up a set of proof-of-con­cept da­ta from a small co­hort of he­pati­tis B pa­tients in a match-up against some heavy­weight ri­vals which got out in front of this race. And right in the front row you’ll find a team from Roche, which paid $200 mil­lion in cash and of­fered an­oth­er $1.5 bil­lion in mile­stones to part­ner with Dicer­na $DR­NA on their RNAi pro­gram for hep B.

Right now it’s look­ing com­pet­i­tive, with lots of big chal­lenges ahead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER